Advertisement

Asialoglycoprotein Receptor and Targeting Strategies

  • Saugandha Das
  • Pawan Kudale
  • Prajakta Dandekar
  • Padma V. DevarajanEmail author
Chapter
Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 39)

Abstract

The asialoglycoprotein receptor is a calcium-dependent, carbohydrate-specific, type C lectin, which is majorly present in the plasma membrane of liver cells (hepatocytes). The high liver specificity, efficient internalization rate, and ready accessibility to the vasculature present great potential of this receptor for use in site-specific targeting of nano-delivery systems for diagnostic and therapeutic applications in liver diseases with negligible nontarget toxicity. This chapter provides a detailed discussion on the receptor expression, structure, binding, ligands, and asialoglycoprotein receptor-mediated hepatocyte-targeted delivery systems. It also discusses the clinical relevance of the receptor in numerous liver afflictions along with its application in liver diagnostics.

Keywords

Asialoglycoprotein ASGP-R Hepatocyte Receptor-mediated targeting Nano-delivery system 

Abbreviations

5-FU

5-Fluorouracil

AA

Antibiotin antibody

AF

Asialofetuin

AG

Arabinogalactan

AI-CAH

Autoimmune-type chronic active hepatitis

AIH

Autoimmune hepatitis

ApoE

Apolipoprotein E

ASGP-R

Asialoglycoprotein receptor

asODN

Antisense oligonucleotides

ASOR

Asialoorosomucoid AuNPs@PDA Gold nanoparticles@Polydopamine

BDICA

Triiodobenzene compound

BNLCL2

Mouse embryonic liver cells

BSA

Bovine serum albumin

C4-Chol

Cholesten-5-yloxy-N-(4-((1-imino-2-d-thiogalactosylethyl)amino) butyl)formamide

CDE

Cyclodextrin conjugated PAMAM dendrimer

CMC

Carboxymethyl chitosan

CMD

Carboxymethyl-dextran

CPDC

Cationic polycarbonate diblock copolymer

CRD

Carbohydrate recognition domain

CTG

Cholesterylated thiogalactoside

DDMAP

Dimyristoyl diacyltrimethylammonium propane

DOX

Doxorubicin

DPEA

Dioleoylphosphatidyl ethanolamine

DTPA

Diethylenetriamine pentaacetic acid

EGFR-ERK

Epidermal growth factor receptor-extracellular signal regulated kinases

Gal

Galactose

GalNAc

N-acetylgalactosamine

GDPA

Gadolinium diethylenetriamine pentaacetic acid

GO

Graphene oxide

H-bond

Hydrogen bond

HBV

Hepatitis B virus

HCC

Hepatocellular carcinoma

HepG2

Hepatocellular carcinoma cell line

HSA

Human serum albumin

IgA

Immunoglobulins A

IL

Interleukin

KC

Kupffer cell

LA

Lactobionic acid

Lac

Lactosaminated

LDL

Low-density lipoproteins

LSP

Liver-specific protein

MHV

Mouse hepatitis virus

MRI

Magnetic resonance imaging

N-HPMA

N-(2hydroxypropyl) methacrylamide

N-LDLPTA

N-lactosyl-dioleoylphosphatidylethanolamine

NPs

Nanoparticles

p(VLA-co-VNI-co-V2DTPA)

Poly(vinylbenzyl-O-b-D-galactopyranosyl-D-gluconamide)-co-N-p-vinylbenzyl-6-(2-(4-dimethylamino)benzaldehydehydrazono)nicotinate-co-5,8-bis(carboxymethyl)-3-oxo-11-(2-oxo-2-((4-vinylbenzyl)amino)ethyl)-1-(4-vinylphenzyl)-2,5,8,11-tetraazatridecan-13-oic acid

PAA

Poly(amidoamine)

PAE/PLGA

Poly(β-amino ester)/poly(lactic-co-glycolic acid)

PEC

Poly(ε-caprolactone)

PEG

Polyethylene glycol

PEG-PEC

Poly(ethylene glycol)-poly(ε-caprolactone)

PEI

Polyethylenimine

PGA

Poly-γ-glutamic acid

PGEA

Poly(glycidyl-ethanolamine)

PLA

Polylactic acid

PLGA

Poly(lactic-co-glycolic acid)

PLL

Poly-L-lysine

PNIPAm

Poly (N-isopropylacrylamide)

PTX

Paclitaxel

RBV

Ribavarin

siRNA

Small interfering RNA

SPECT

Single-photon emission computed tomography

TAB

Tetraacetylbromo

TNF

Tumor necrosis factor

TPGS

Tocopherol polyethylene glycol succinate

References

  1. 1.
    D’Souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting - Strategies and applications. J Control Release. 2015;203:126–39.PubMedCrossRefGoogle Scholar
  2. 2.
    Kedderis GL, Held SD. Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol Appl Pharmacol. 1996;140(1):124–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem. 1982;51(1):531–54.PubMedCrossRefGoogle Scholar
  4. 4.
    Grewal PK. The Ashwell–Morell receptor. In: Methods in enzymology, vol. 479: Academic Press; 2010. p. 223–41. United States of America.Google Scholar
  5. 5.
    Spiess M. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry. 1990;29(43):10009–18.PubMedCrossRefGoogle Scholar
  6. 6.
    Roggenbuck D, Mytilinaiou MG, Lapin SV, Reinhold D, Conrad K. Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity. Auto Immun Highlights. 2012;3(3):119.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Weigel PH. Characterization of the asialoglycoprotein receptor on isolated rat hepatocytes. J Biol Chem. 1980;255(13):6111–20.PubMedGoogle Scholar
  8. 8.
    Li Y, Huang G, Diakur J, Wiebe LI. Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv. 2008;5(4):299–302.PubMedCrossRefGoogle Scholar
  9. 9.
    Schwartz AL, Ashwell G. The hepatic asialoglycoprotein receptor. Crit Rev Biochem. 1984;16(3):207–33.CrossRefGoogle Scholar
  10. 10.
    Park JH, Cho EW, Shin SY, Lee YJ, Kim KL. Detection of the asialoglycoprotein receptor on cell lines of extrahepatic origin. Biochem Biophys Res Commun. 1998;244(1):304–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Rigopoulou EI, Roggenbuck D, Smyk DS, Liaskos C, Mytilinaiou MG, Feist E, Conrad K, Bogdanos DP. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. Autoimmun Rev. 2012;12(2):260–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Dotzauer A, Gebhardt U, Bieback K, Göttke U, Kracke A, Mages J, Lemon SM, Vallbracht A. Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor. J Virol. 2000;74(23):10950–7.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Yang J, Wang F, Tian L, Su J, Zhu X, Lin L, Ding X, Wang X, Wang S. Fibronectin and asialoglyprotein receptor mediate hepatitis B surface antigen binding to the cell surface. Arch Virol. 2010;155(6):881–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Treichel U, zum Büschenfelde KH, Stockert RJ, Poralla T, Gerken G. The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. J Gen Virol. 1994;75(11):3021–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev. 1995;75(3):591–609.PubMedCrossRefGoogle Scholar
  16. 16.
    Saunier B, Triyatni M, Ulianich L, Maruvada P, Yen P, Kohn LD. Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol. 2003;77(1):546–59.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Becker S, Spiess M, Klenk HD. The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J Gen Virol. 1995;76(2):393–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Grewal PK, Uchiyama S, Ditto D, Varki N, Le DT, Nizet V, Marth JD. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008;14(6):648.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Ueno S, Mojic M, Ohashi Y, Higashi N, Hayakawa Y, Irimura T. Asialoglycoprotein receptor promotes cancer metastasis by activating the EGFR–ERK pathway. Cancer Res. 2011;71(20):6419–27.PubMedCrossRefGoogle Scholar
  20. 20.
    Nakaya R, Kohgo Y, Mogi Y, Nakajima M, Kato J, Niitsu Y. Regulation of asialoglycoprotein receptor synthesis by inflammation-related cytokines in HepG2 cells. J Gastroenterol. 1994;29(1):24–30.PubMedCrossRefGoogle Scholar
  21. 21.
    Poralla T, Treichel U, Löhr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis. 1991;11(03):215–22. Thieme Medical Publishers, Inc.PubMedCrossRefGoogle Scholar
  22. 22.
    McFarlane IG, McFarlane BM, Major GN, Tolley P, Williams R. Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol. 1984;55(2):347.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Witzigmann D, Quagliata L, Schenk SH, Quintavalle C, Terracciano LM, Huwyler J. Variable asialoglycoprotein receptor 1 expression in liver disease: implications for therapeutic intervention. Hepatol Res. 2016;46(7):686–96.PubMedCrossRefGoogle Scholar
  24. 24.
    Villalta D, Mytilinaiou MG, Elsner M, Hentschel C, Cuccato J, Somma V, Schierack P, Roggenbuck D, Bogdanos DP. Autoantibodies to asialoglycoprotein receptor (ASGPR) in patients with autoimmune liver diseases. Clin Chim Acta. 2015;450:1–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Sawamura T, Nakada H, Hazama H, Shiozaki Y, Sameshima Y, Tashiro Y. Hyperasialoglycoproteinemia in patients with chronic liver diseases and/or liver cell carcinoma: asialoglycoprotein receptor in cirrhosis and liver cell carcinoma. Gastroenterology. 1984;87(6):1217–21.PubMedCrossRefGoogle Scholar
  26. 26.
    Virgolini I, Müller C, Klepetko W, Angelberger P, Bergmann H, O’Grady J, Sinzinger H. Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand. Br J Cancer. 1990;61(6):937.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    DODEUR M, DURAND D, DUMONT J, DURAND G, FEGER J, AGNERAY J. Effects of streptozotocin-induced diabetes mellitus on the binding and uptake of asialoorosomucoïd by isolated hepatocytes from rats. Eur J Biochem. 1982;123(2):383–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Burgess JB, Baenziger JU, Brown WR. Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis. Hepatology. 1992;15(4):702–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Marshall JS, Green AM, Pensky J, Williams S, Zinn A, Carlson DM. Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage. J Clin Invest. 1974;54(3):555–62.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Trere D, Fiume L, De Giorgi LB, Di Stefano G, Migaldi M, Derenzini M. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. Br J Cancer. 1999;81(3):404.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Bischoff J, Lodish HF. Two asialoglycoprotein receptor polypeptides in human hepatoma cells. J Biol Chem. 1987;262(24):11825–32.PubMedGoogle Scholar
  32. 32.
    Meier M, Bider MD, Malashkevich VN, Spiess M, Burkhard P. Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J Mol Biol. 2000;300(4):857–65.PubMedCrossRefGoogle Scholar
  33. 33.
    Spiess M, Lodish HF. Sequence of a second human asialoglycoprotein receptor: conservation of two receptor genes during evolution. Proc Natl Acad Sci. 1985;82(19):6465–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Harris RL, Van den Berg CW, Bowen DJ. ASGR1 and ASGR2, the genes that encode the asialoglycoprotein receptor (Ashwell receptor), are expressed in peripheral blood monocytes and show interindividual differences in transcript profile. Mol Biol Int. 2012;2012:1.CrossRefGoogle Scholar
  35. 35.
    Henis YI, Katzir Z, Shia MA, Lodish HF. Oligomeric structure of the human asialoglycoprotein receptor: nature and stoichiometry of mutual complexes containing H1 and H2 polypeptides assessed by fluorescence photobleaching recovery. J Cell Biol. 1990;111(4):1409–18.PubMedCrossRefGoogle Scholar
  36. 36.
    Braiterman LT, Chance SC, Porter WR, Lee YC, Townsend RR, Hubbard AL. The major subunit of the rat asialoglycoprotein receptor can function alone as a receptor. J Biol Chem. 1989;264(3):1682–8.PubMedGoogle Scholar
  37. 37.
    Ishibashi S, Hammer RE, Herz J. Asialoglycoprotein receptor deficiency in mice lacking the minor receptor subunit. J Biol Chem. 1994;269(45):27803–6.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Shia MA, Lodish HF. The two subunits of the human asialoglycoprotein receptor have different fates when expressed alone in fibroblasts. Proc Natl Acad Sci. 1989;86(4):1158–62.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Tozawa RI, Ishibashi S, Osuga JI, Yamamoto K, Yagyu H, Ohashi K, Tamura Y, Yahagi N, Iizuka Y, Okazaki H, Harada K. Asialoglycoprotein receptor deficiency in mice lacking the major receptor subunit its obligate requirement for the stable expression of oligomeric receptor. J Biol Chem. 2001;276(16):12624–8.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Valladeau J, Duvert-Frances V, Pin JJ, Kleijmeer MJ, Ait-Yahia S, Ravel O, Vincent C, Vega F, Helms A, Gorman D, Zurawski SM. Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis. J Immunol. 2001;167(10):5767–74.PubMedCrossRefGoogle Scholar
  41. 41.
    Massarelli I, Murgia L, Bianucci A, Chiellini F, Chiellini E. Understanding the selectivity mechanism of the human asialoglycoprotein receptor (ASGP-R) toward gal-and man-type ligands for predicting interactions with exogenous sugars. Int J Mol Sci. 2007;8(1):13–28.PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Mcabee DD, Jiang X, WALSH KB. Lactoferrin binding to the rat asialoglycoprotein receptor requires the receptor’s lectin properties. Biochem J. 2000;348(1):113–7.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Onizuka T, Shimizu H, Moriwaki Y, Nakano T, Kanai S, Shimada I, Takahashi H. NMR study of ligand release from asialoglycoprotein receptor under solution conditions in early endosomes. FEBS J. 2012;279(15):2645–56.PubMedCrossRefGoogle Scholar
  44. 44.
    Weigel PH, Yik JH. Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochim Biophys Acta. 2002;1572(2–3):341–63.PubMedCrossRefGoogle Scholar
  45. 45.
    Spiess M, Schwartz AL, Lodish HF. Sequence of human asialoglycoprotein receptor cDNA. An internal signal sequence for membrane insertion. J Biol Chem. 1985;260(4):1979–82.PubMedGoogle Scholar
  46. 46.
    Ramadugu SK, Chung YH, Fuentes EJ, Rice KG, Margulis CJ. In silico prediction of the 3D structure of trimeric asialoglycoprotein receptor bound to triantennary oligosaccharide. J Am Chem Soc. 2010;132(26):9087–95.PubMedCrossRefGoogle Scholar
  47. 47.
    Bider MD, Wahlberg JM, Kammerer RA, Spiess M. The oligomerization domain of the asialoglycoprotein receptor preferentially forms 2: 2 heterotetramers in vitro. J Biol Chem. 1996;271(50):31996–2001.PubMedCrossRefGoogle Scholar
  48. 48.
    D’Souza AA, Jain P, Galdhar CN, Samad A, Degani MS, Devarajan PV. Comparative in silico–in vivo evaluation of ASGP-R ligands for hepatic targeting of curcumin Gantrez nanoparticles. AAPS J. 2013;15(3):696–706.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Braun JR, Willnow TE, Ishibashi S, Ashwell G, Herz J. The major subunit of the asialoglycoprotein receptor is expressed on the hepatocellular surface in mice lacking the minor receptor subunit. J Biol Chem. 1996;271(35):21160–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Kolatkar AR, Weis WI. Structural basis of galactose recognition by C-type animal lectins. J Biol Chem. 1996;271(12):6679–85.PubMedCrossRefGoogle Scholar
  51. 51.
    Huang X, Leroux JC, Castagner B. Well-defined multivalent ligands for hepatocytes targeting via asialoglycoprotein receptor. Bioconjug Chem. 2016;28(2):283–95.PubMedCrossRefGoogle Scholar
  52. 52.
    Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol. 2008;8(11):874.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Weis WI, Taylor ME, Drickamer K. The C-type lectin superfamily in the immune system. Immunol Rev. 1998;163(1):19–34.PubMedCrossRefGoogle Scholar
  54. 54.
    Rohilla R, Garg T, Goyal AK, Rath G. Herbal and polymeric approaches for liver-targeting drug delivery: novel strategies and their significance. Drug Deliv. 2016;23(5):1645–61.PubMedGoogle Scholar
  55. 55.
    Maitani Y, Kawano K, Yamada K, Nagai T, Takayama K. Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells. J Control Release. 2001;75(3):381–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Selim KK, Ha YS, Kim SJ, Chang Y, Kim TJ, Lee GH, Kang IK. Surface modification of magnetite nanoparticles using lactobionic acid and their interaction with hepatocytes. Biomaterials. 2007;28(4):710–6.CrossRefGoogle Scholar
  57. 57.
    Li M, Zhang W, Wang B, Gao Y, Song Z, Zheng QC. Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma. Int J Nanomedicine. 2016;11:5645.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Hu HM, Zhang X, Zhong NQ, Pan SR. Study on galactose–poly (ethylene glycol)–poly (L-lysine) as novel gene vector for targeting hepatocytes in vitro. J Biomater Sci Polym Ed. 2012;23(5):677–95.PubMedCrossRefGoogle Scholar
  59. 59.
    Wu GY, Wu CH. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J Biol Chem. 1987;262(10):4429–32.PubMedGoogle Scholar
  60. 60.
    Robinson MA, Charlton ST, Garnier P, Wang XT, Davis SS, Perkins AC, Frier M, Duncan R, Savage TJ, Wyatt DA, Watson SA. LEAPT: lectin-directed enzyme-activated prodrug therapy. Proc Natl Acad Sci. 2004;101(40):14527–32.PubMedCrossRefGoogle Scholar
  61. 61.
    Huang Y. Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids. 2017;6:116–32.PubMedCrossRefGoogle Scholar
  62. 62.
    Ivanenkov YA, Maklakova SY, Beloglazkina EK, Zyk NV, Nazarenko AG, Tonevitsky AG, Kotelianski VE, Majouga AG. Development of liver cell-targeted drug delivery systems: experimental approaches. Russ Chem Rev. 2017;86(8):750.CrossRefGoogle Scholar
  63. 63.
    Fiume L, Di Stefano G, inventors; UNIVERSITA’DI BOLOGNA DIPARTIMENTO DI PATOLOGIA SPERIMENTALE, assignee. Use of conjugates of doxorubicin with lactosaminated albumin. United States patent application US 12/067,211. 2008 Sep 18.Google Scholar
  64. 64.
    Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem. 2008;15(18):1802–26.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Fiume L, Mattioli A, Balboni PG, Tognon M, Barbanti-Brodano G, De Vries J, Wieland T. Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin. FEBS Lett. 1979;103(1):47–51.PubMedCrossRefGoogle Scholar
  66. 66.
    Fiume L, Mattioli A, Busi C, Accorsi C. Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate (ara-AMP) in mouse liver. Gut. 1984;25(12):1392–8.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Muro S. Challenges in design and characterization of ligand-targeted drug delivery systems. J Control Release. 2012;164(2):125–37.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Wu J, Yuan J, Ye B, Wu Y, Xu Z, Chen J, Chen J. Dual-responsive core crosslinking glycopolymer-drug conjugates nanoparticles for precise hepatocarcinoma therapy. Front Pharmacol. 2018;9Google Scholar
  69. 69.
    Ishihara T, Kano A, Obara K, Saito M, Chen X, Park TG, Akaike T, Maruyama A. Nuclear localization and antisense effect of PNA internalized by ASGP-R-mediated endocytosis with protein/DNA conjugates. J Control Release. 2011;155(1):34–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Ma Y, Chen H, Su S, Wang T, Zhang C, Fida G, Cui S, Zhao J, Gu Y. Galactose as Broad ligand for multiple tumor imaging and therapy. J Cancer. 2015;6(7):658.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Willoughby JL, Chan A, Sehgal A, Butler JS, Nair JK, Racie T, Shulga-Morskaya S, Nguyen T, Qian K, Yucius K, Charisse K. Evaluation of GalNAc-siRNA conjugate activity in pre-clinical animal models with reduced asialoglycoprotein receptor expression. Mol Ther. 2018;26(1):105–14.PubMedCrossRefGoogle Scholar
  72. 72.
    Varshosaz J, Asheghali F. Chondroitin/doxorubicin nanoparticulate polyelectrolyte complex for targeted delivery to HepG2 cells. IET Nanobiotechnol. 2016;11(2):164–72.CrossRefGoogle Scholar
  73. 73.
    Yu CY, Wang YM, Li NM, Liu GS, Yang S, Tang GT, He DX, Tan XW, Wei H. In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy. Mol Pharm. 2014;11(2):638–44.PubMedCrossRefGoogle Scholar
  74. 74.
    Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958–61.PubMedCrossRefGoogle Scholar
  75. 75.
    Ong ZY, Yang C, Gao SJ, Ke XY, Hedrick JL, Yan YY. Galactose-functionalized cationic polycarbonate diblock copolymer for targeted gene delivery to hepatocytes. Macromol Rapid Commun. 2013;34(21):1714–20.PubMedCrossRefGoogle Scholar
  76. 76.
    Yang XC, Niu YL, Zhao NN, Mao C, Xu FJ. A biocleavable pullulan-based vector via ATRP for liver cell-targeting gene delivery. Biomaterials. 2014;35(12):3873–84.PubMedCrossRefGoogle Scholar
  77. 77.
    Dehshahri A, Kazemi Oskuee R, Thomas Shier W, Ramezani M. β-Galactosylated alkyl-oligoamine derivatives of polyethylenimine enhanced pDNA delivery into hepatic cells with reduced toxicity. Curr Nanosci. 2012;8(4):548–55.CrossRefGoogle Scholar
  78. 78.
    Di Stefano G, Colonna FP, Bongini A, Busi C, Mattioli A, Fiume L. Ribavirin conjugated with lactosaminated poly-L-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis. Biochem Pharmacol. 1997;54(3):357–63.PubMedCrossRefGoogle Scholar
  79. 79.
    Ma J, Huang C, Yao X, Shi C, Sun L, Yuan L, Lei P, Zhu H, Liu H, Wu X, Ning Q. Inhibition of hepatitis B virus and induction of hepatoma cell apoptosis by ASGPR-directed delivery of shRNAs. PLoS One. 2012;7(10):e46096.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Tomiya N, Jardim JG, Hou J, Pastrana-Mena R, Dinglasan RR, Lee YC. Liver-targeting of primaquine-(poly-γ-glutamic acid) and its degradation in rat hepatocytes. Bioorg Med Chem. 2013;21(17):5275–81.PubMedCrossRefGoogle Scholar
  81. 81.
    Hashida M, Hirabayashi H, Nishikawa M, Takakura Y. Targeted delivery of drugs and proteins to the liver via receptor-mediated endocytosis. J Control Release. 1997;46(1–2):129–37.CrossRefGoogle Scholar
  82. 82.
    Nishikawa M, Kamijo A, Fujita T, Takakura Y, Sezaki H, Hashida M. Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. Pharm Res. 1993;10(9):1253–61.PubMedCrossRefGoogle Scholar
  83. 83.
    McMahon A, O’neill MJ, Gomez E, Donohue R, Forde D, Darcy R, O’driscoll CM. Targeted gene delivery to hepatocytes with galactosylated amphiphilic cyclodextrins. J Pharm Pharmacol. 2012;64(8):1063–73.PubMedCrossRefGoogle Scholar
  84. 84.
    Popielarski SR, Pun SH, Davis ME. A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 1. Synthesis and characterization. Bioconjug Chem. 2005;16(5):1063–70.PubMedCrossRefGoogle Scholar
  85. 85.
    Biessen EA, Beuting DM, Vietsch H, Bijsterbosch MK, Van Berkel TJ. Specific targeting of the antiviral drug 5-iodo 2′-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine. J Hepatol. 1994;21(5):806–15.PubMedCrossRefGoogle Scholar
  86. 86.
    Murao A, Nishikawa M, Managit C, Wong J, Kawakami S, Yamashita F, Hashida M. Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: effect of lipid composition. Pharm Res. 2002;19(12):1808–14.PubMedCrossRefGoogle Scholar
  87. 87.
    Naicker K, Ariatti M, Singh M. PEGylated galactosylated cationic liposomes for hepatocytic gene delivery. Colloids Surf B: Biointerfaces. 2014;122:482–90.PubMedCrossRefGoogle Scholar
  88. 88.
    Nishikawa M, Ohtsubo Y, Ohno J, Fujita T, Koyama Y, Yamashita F, Hashida M, Sezaki H. Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice. Int J Pharm. 1992;85(1–3):75–85.CrossRefGoogle Scholar
  89. 89.
    Zhang YN, Poon W, Tavares AJ, McGilvray ID, Chan WC. Nanoparticle–liver interactions: cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332–48.PubMedCrossRefGoogle Scholar
  90. 90.
    Arima H, Motoyama K, Higashi T. Potential use of cyclodextrins as drug carriers and active pharmaceutical ingredients. Chem Pharm Bull. 2017;65(4):341–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Quan G, Pan X, Wang Z, Wu Q, Li G, Dian L, Chen B, Wu C. Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery. J Nanobiotechnol. 2015;13(1):7.CrossRefGoogle Scholar
  92. 92.
    Zheng G, Zhao R, Xu A, Shen Z, Chen X, Shao J. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy. Eur J Pharm Sci. 2018;111:492–502.PubMedCrossRefGoogle Scholar
  93. 93.
    Zhang C, An T, Wang D, Wan G, Zhang M, Wang H, Zhang S, Li R, Yang X, Wang Y. Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly (β-amino ester)/poly (lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma. J Control Release. 2016;226:193–204.PubMedCrossRefGoogle Scholar
  94. 94.
    Xue WJ, Feng Y, Wang F, Guo YB, Li P, Wang L, Liu YF, Wang ZW, Yang YM, Mao QS. Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma. Sci Rep. 2016;6:22149.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Zhu D, Tao W, Zhang H, Liu G, Wang T, Zhang L, Zeng X, Mei L. Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Acta Biomater. 2016;30:144–54.PubMedCrossRefGoogle Scholar
  96. 96.
    Tsend-Ayush A, Zhu X, Ding Y, Yao J, Yin L, Zhou J, Yao J. Lactobionic acid-conjugated TPGS nanoparticles for enhancing therapeutic efficacy of etoposide against hepatocellular carcinoma. Nanotechnology. 2017;28(19):195602.PubMedCrossRefGoogle Scholar
  97. 97.
    Chen W, Zou Y, Meng F, Cheng R, Deng C, Feijen J, Zhong Z. Glyco-nanoparticles with sheddable saccharide shells: a unique and potent platform for hepatoma-targeting delivery of anticancer drugs. Biomacromolecules. 2014;15(3):900–7.PubMedCrossRefGoogle Scholar
  98. 98.
    Guan M, Zhu QL, Liu Y, Bei YY, Gu ZL, Zhang XN, Zhang Q. Uptake and transport of a novel anticancer drug-delivery system: lactosyl-norcantharidin-associated N-trimethyl chitosan nanoparticles across intestinal Caco-2 cell monolayers. Int J Nanomedicine. 2012;7:1921.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Thapa B, Kumar P, Zeng H, Narain R. Asialoglycoprotein receptor-mediated gene delivery to hepatocytes using galactosylated polymers. Biomacromolecules. 2015;16(9):3008–20.PubMedCrossRefGoogle Scholar
  100. 100.
    Liang HF, Chen CT, Chen SC, Kulkarni AR, Chiu YL, Chen MC, Sung HW. Paclitaxel-loaded poly (γ-glutamic acid)-poly (lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials. 2006;27(9):2051–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Zhu X, Du Y, Yu R, Liu P, Shi D, Chen Y, Wang Y, Huang F. Galactosylated chitosan oligosaccharide nanoparticles for hepatocellular carcinoma cell-targeted delivery of adenosine triphosphate. Int J Mol Sci. 2013;14(8):15755–66.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Ding J, Xiao C, Li Y, Cheng Y, Wang N, He C, Zhuang X, Zhu X, Chen X. Efficacious hepatoma-targeted nanomedicine self-assembled from galactopeptide and doxorubicin driven by two-stage physical interactions. J Control Release. 2013;169(3):193–203.PubMedCrossRefGoogle Scholar
  103. 103.
    Shi L, Tang C, Yin C. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma. Biomaterials. 2012;33(30):7594–604.PubMedCrossRefGoogle Scholar
  104. 104.
    Chittasupho C, Jaturanpinyo M, Mangmool S. Pectin nanoparticle enhances cytotoxicity of methotrexate against hepG2 cells. Drug Deliv. 2013;20(1):1–9.PubMedCrossRefGoogle Scholar
  105. 105.
    Huang L, Wang Y, Ling X, Chaurasiya B, Yang C, Du Y, Tu J, Xiong Y, Sun C. Efficient delivery of paclitaxel into ASGPR over-expressed cancer cells using reversibly stabilized multifunctional pullulan nanoparticles. Carbohydr Polym. 2017;159:178–87.PubMedCrossRefGoogle Scholar
  106. 106.
    Pranatharthiharan S, Patel MD, Malshe VC, Pujari V, Gorakshakar A, Madkaikar M, Ghosh K, Devarajan PV. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma. Drug Deliv. 2017;24(1):20–9.PubMedCrossRefGoogle Scholar
  107. 107.
    Jain N, Rajoriya V, Jain PK, Jain AK. Lactosaminated-N-succinyl chitosan nanoparticles for hepatocyte-targeted delivery of acyclovir. J Nanopart Res. 2014;16(1):2136.CrossRefGoogle Scholar
  108. 108.
    Li X, Wu Q, Chen Z, Gong X, Lin X. Preparation, characterization and controlled release of liver-targeting nanoparticles from the amphiphilic random copolymer. Polymer. 2008;49(22):4769–75.CrossRefGoogle Scholar
  109. 109.
    Joshi VM, Devarajan PV. Receptor-mediated hepatocyte-targeted delivery of primaquine phosphate nanocarboplex using a carbohydrate ligand. Drug Deliv Transl Res. 2014;4(4):353–64.PubMedCrossRefGoogle Scholar
  110. 110.
    Varshosaz J, Hassanzadeh F, Sadeghi H, Khadem M. Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma. J Liposome Res. 2012;22(3):224–36.PubMedCrossRefGoogle Scholar
  111. 111.
    Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, Xi Y, Li Y. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009;30(2):226–32.PubMedCrossRefGoogle Scholar
  112. 112.
    Chen S, Tam YY, Lin PJ, Leung AK, Tam YK, Cullis PR. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. J Control Release. 2014;196:106–12.PubMedCrossRefGoogle Scholar
  113. 113.
    Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, Jayaraman M, Rajeev KG, Cantley WL, Dorkin JR, Butler JS. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357–64.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Oh H, Jo HY, Park J, Kim DE, Cho JY, Kim PH, Kim KS. Galactosylated liposomes for targeted co-delivery of doxorubicin/vimentin siRNA to hepatocellular carcinoma. Nano. 2016;6(8):141.Google Scholar
  115. 115.
    Zhou X, Zhang M, Bryant Yung HL, Zhou C, Lee LJ, Lee RJ. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int J Nanomedicine. 2012;7:5465.PubMedPubMedCentralGoogle Scholar
  116. 116.
    Hai L, Zhang ZR, Wang S, Xiao X, Wu Y. Synthesis of multivalent galactosides as targeting ligand for gene delivery. Synth Commun. 2010;40(12):1802–11.CrossRefGoogle Scholar
  117. 117.
    Sun X, Hai L, Wu Y, Hu HY, Zhang ZR. Targeted gene delivery to hepatoma cells using galactosylated liposome-polycation-DNA complexes (LPD). J Drug Target. 2005;13(2):121–8.PubMedCrossRefGoogle Scholar
  118. 118.
    Zhang X, Guo S, Fan R, Yu M, Li F, Zhu C, Gan Y. Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells. Biomaterials. 2012;33(29):7103–14.PubMedCrossRefGoogle Scholar
  119. 119.
    Zhang Y, Qi XR, Gao Y, Wei L, Maitani Y, Nagai T. Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. J Control Release. 2007;117(2):281–90.PubMedCrossRefGoogle Scholar
  120. 120.
    Cho HA, Park IS, Kim TW, Oh YK, Yang KS, Kim JS. Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-κB-inducing kinase-specific siRNA using liver-targeting liposomes. Arch Pharm Res. 2009;32(7):1077–86.PubMedCrossRefGoogle Scholar
  121. 121.
    Suriano F, Pratt R, Tan JP, Wiradharma N, Nelson A, Yang YY, Dubois P, Hedrick JL. Synthesis of a family of amphiphilic glycopolymers via controlled ring-opening polymerization of functionalized cyclic carbonates and their application in drug delivery. Biomaterials. 2010;31(9):2637–45.PubMedCrossRefGoogle Scholar
  122. 122.
    Zhong Y, Yang W, Sun H, Cheng R, Meng F, Deng C, Zhong Z. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells. Biomacromolecules. 2013;14(10):3723–30.PubMedCrossRefGoogle Scholar
  123. 123.
    Liu S, Huang Y, Chen X, Zhang L, Jing X. Lactose mediated liver-targeting effect observed by ex vivo imaging technology. Biomaterials. 2010;31(9):2646–54.PubMedCrossRefGoogle Scholar
  124. 124.
    Oishi M, Nagatsugi F, Sasaki S, Nagasaki Y, Kataoka K. Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages. Chembiochem. 2005;6(4):718–25.PubMedCrossRefGoogle Scholar
  125. 125.
    Zou Y, Song Y, Yang W, Meng F, Liu H, Zhong Z. Galactose-installed photo-crosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice. J Control Release. 2014;193:154–61.PubMedCrossRefGoogle Scholar
  126. 126.
    Yang R, Meng F, Ma S, Huang F, Liu H, Zhong Z. Galactose-decorated cross-linked biodegradable poly (ethylene glycol)-b-poly (ε-caprolactone) block copolymer micelles for enhanced hepatoma-targeting delivery of paclitaxel. Biomacromolecules. 2011;12(8):3047–55.PubMedCrossRefGoogle Scholar
  127. 127.
    Craparo EF, Triolo D, Pitarresi G, Giammona G, Cavallaro G. Galactosylated micelles for a ribavirin prodrug targeting to hepatocytes. Biomacromolecules. 2013;14(6):1838–49.PubMedCrossRefGoogle Scholar
  128. 128.
    Villa R, Cerroni B, Viganò L, Margheritelli S, Abolafio G, Oddo L, Paradossi G, Zaffaroni N. Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells. Colloids Surf B: Biointerfaces. 2013;110:434–42.PubMedCrossRefGoogle Scholar
  129. 129.
    Wei W, Yue ZG, Qu JB, Yue H, Su ZG, Ma GH. Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation. Nanomedicine. 2010;5(4):589–96.PubMedCrossRefGoogle Scholar
  130. 130.
    Duan C, Gao J, Zhang D, Jia L, Liu Y, Zheng D, Liu G, Tian X, Wang F, Zhang Q. Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin. Biomacromolecules. 2011;12(12):4335–43.PubMedCrossRefGoogle Scholar
  131. 131.
    Managit C, Kawakami S, Yamashita F, Hashida M. Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells. Int J Pharm. 2005;301(1–2):255–61.PubMedCrossRefGoogle Scholar
  132. 132.
    Liu D, Hu H, Zhang J, Zhao X, Tang X, Chen D. Drug pH-sensitive release in vitro and targeting ability of polyamidoamine dendrimer complexes for tumor cells. Chem Pharm Bull. 2011;59(1):63–71.PubMedCrossRefGoogle Scholar
  133. 133.
    Kuruvilla SP, Tiruchinapally G, Crouch AC, ElSayed ME, Greve JM. Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model. PLoS One. 2017;12(8):e0181944.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Nasr M, Nafee N, Saad H, Kazem A. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. Eur J Pharm Biopharm. 2014;88(1):216–25.PubMedCrossRefGoogle Scholar
  135. 135.
    Peng J, Wang K, Tan W, He X, He C, Wu P, Liu F. Identification of live liver cancer cells in a mixed cell system using galactose-conjugated fluorescent nanoparticles. Talanta. 2007;71(2):833–40.PubMedCrossRefGoogle Scholar
  136. 136.
    Yang SH, Heo D, Lee E, Kim E, Lim EK, Lee YH, Haam S, Suh JS, Huh YM, Yang J, Park SW. Galactosylated manganese ferrite nanoparticles for targeted MR imaging of asialoglycoprotein receptor. Nanotechnology. 2013;24(47):475103.PubMedCrossRefGoogle Scholar
  137. 137.
    Kikkeri R, Lepenies B, Adibekian A, Laurino P, Seeberger PH. In vitro imaging and in vivo liver targeting with carbohydrate capped quantum dots. J Am Chem Soc. 2009;131(6):2110–2.CrossRefGoogle Scholar
  138. 138.
    Ketkar-Atre A, Struys T, Dresselaers T, Hodenius M, Mannaerts I, Ni Y, Lambrichts I, Van Grunsven LA, De Cuyper M, Himmelreich U. In vivo hepatocyte MR imaging using lactose functionalized magnetoliposomes. Biomaterials. 2014;35(3):1015–24.PubMedCrossRefGoogle Scholar
  139. 139.
    Kim EM, Jeong HJ, Kim SL, Sohn MH, Nah JW, Bom HS, Park IK, Cho CS. Asialoglycoprotein-receptor-targeted hepatocyte imaging using 99mTc galactosylated chitosan. Nucl Med Biol. 2006;33(4):529–34.PubMedCrossRefGoogle Scholar
  140. 140.
    Sasaki N, Shiomi S, Iwata Y, Nishiguchi S, Kuroki T, Kawabe J, Ochi H. Clinical usefulness of scintigraphy with^ 9^ 9^ mTc-galactosyl-human serum albumin for prognosis of cirrhosis of the liver. J Nucl Med. 1999;40(10):1652–6.PubMedGoogle Scholar
  141. 141.
    Stadalnik RC, Vera DR, Woodle ES, Trudeau WL, Porter BA, Ward RE, Krohn KA, O’Grady LF. Technetium-99m NGA functional hepatic imaging: preliminary clinical experience. J Nucl Med. 1985;26(11):1233–42.PubMedGoogle Scholar
  142. 142.
    Jeong JM, Hong MK, Lee J, Son M, So Y, Lee DS, Chung JK, Lee MC. 99mTc-neolactosylated human serum albumin for imaging the hepatic asialoglycoprotein receptor. Bioconjug Chem. 2004;15(4):850–5.PubMedCrossRefGoogle Scholar
  143. 143.
    Liang J, Zhang X, Miao Y, Li J, Gan Y. Lipid-coated iron oxide nanoparticles for dual-modal imaging of hepatocellular carcinoma. Int J Nanomedicine. 2017;12:2033.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Kouda K, Kil Ha-Kawa S, Tanaka Y. Increased technetium-99m-GSA uptake per hepatocyte in rats with administration of dimethylnitrosamine or hepatocyte growth factor. J Nucl Med. 1998;39:1463–7.PubMedGoogle Scholar
  145. 145.
    Haubner R, Vera DR, Farshchi-Heydari S, Helbok A, Rangger C, Putzer D, Virgolini IJ. Development of 68 Ga-labelled DTPA galactosyl human serum albumin for liver function imaging. Eur J Nucl Med Mol Imaging. 2013;40(8):1245–55.PubMedCrossRefGoogle Scholar
  146. 146.
    Song MG, Jang SA, Youn H, Lee YS, Jeong JM, Chung JK, Kratz F, Lee DS, Kang KW. Enhancement of targeting ability of 64Cu-lactosaminated HSA to asialoglycoprotein receptor positive cells by addition of lactosamine residues. J Nucl Med. 2014;55(supplement 1):1046.Google Scholar
  147. 147.
    Jung Y, Hwang HS, Na K. Galactosylated iodine-based small molecule IV CT contrast agent for bile duct imaging. Biomaterials. 2018;160:15–23.PubMedCrossRefGoogle Scholar
  148. 148.
    Yoshinori M, Masaharu M, Yuri H, Sayoko N, Nao S, Makoto H. Molecular imaging contrast media for visualization of liver function. Magn Reson Imaging. 2010;28(5):708–15.PubMedCrossRefGoogle Scholar
  149. 149.
    Zhang D, Guo Z, Zhang P, Li Y, Su X, You L, Gao M, Liu C, Wu H, Zhang X. Simplified quantification method for in vivo SPECT/CT imaging of asialoglycoprotein receptor with 99m Tc-p (VLA-co-VNI) to assess and stage hepatic fibrosis in mice. Sci Rep. 2016;6:25377.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Wu LJ, Pan YD, Pei XY, Chen H, Nguyen S, Kashyap A, Liu J, Wu J. Capturing circulating tumor cells of hepatocellular carcinoma. Cancer Lett. 2012;326(1):17–22.PubMedCrossRefGoogle Scholar
  151. 151.
    Xu W, Cao L, Chen L, Li J, Zhang XF, Qian HH, Kang XY, Zhang Y, Liao J, Shi LH, Yang YF. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res. 2011;17(11):3783–93.PubMedCrossRefGoogle Scholar
  152. 152.
    Deal KA, Cristel ME, Welch MJ. Cellular distribution of 111In-LDTPA galactose BSA in normal and asialoglycoprotein receptor-deficient mouse liver. Nucl Med Biol. 1998;25(4):379–85.PubMedCrossRefGoogle Scholar
  153. 153.
    Richard C, Chaumet-Riffaud P, Belland A, Parat A, Contino-Pepin C, Bessodes M, Scherman D, Pucci B, Mignet N. Amphiphilic perfluoroalkyl carbohydrates as new tools for liver imaging. Int J Pharm. 2009;379(2):301–8.PubMedCrossRefGoogle Scholar
  154. 154.
    Iimuro Y, Kashiwagi T, Yamanaka J, Hirano T, Saito S, Sugimoto T, Watanabe S, Kuroda N, Okada T, Asano Y, Uyama N. Preoperative estimation of asialoglycoprotein receptor expression in the remnant liver from CT/99mTc-GSA SPECT fusion images correlates well with postoperative liver function parameters. J Hepatobiliary Pancreat Sci. 2010;17(5):673–81.PubMedCrossRefGoogle Scholar
  155. 155.
    Ogawara KI, Nishikawa M, Takakura Y, Hashida M. Pharmacokinetic analysis of hepatic uptake of galactosylated bovine serum albumin in a perfused rat liver. J Control Release. 1998;50(1–3):309–17.PubMedCrossRefGoogle Scholar
  156. 156.
    Ha-Kawa SK, Tanaka Y, Hasebe S, Kuniyasu Y, Koizumi K, Ishii Y, Yamamoto K, Kashiwagi T, Ito A, Kudo M, Ikekubo K. Compartmental analysis of asialoglycoprotein receptor scintigraphy for quantitative measurement of liver function: a multicentre study. Eur J Nucl Med. 1997;24(2):130–7.PubMedCrossRefGoogle Scholar
  157. 157.
    Vera DR, Stadalnik RC, Metz CE, Pimstone NR. Diagnostic performance of a receptor-binding radiopharmacokinetic model. J Nucl Med. 1996;37(1):160–4.PubMedGoogle Scholar
  158. 158.
    Sharma A, Kim EJ, Shi H, Lee JY, Chung BG, Kim JS. Development of a theranostic prodrug for colon cancer therapy by combining ligand-targeted delivery and enzyme-stimulated activation. Biomaterials. 2018;155:145–51.PubMedCrossRefGoogle Scholar
  159. 159.
    Zeng Y, Zhang D, Wu M, Liu Y, Zhang X, Li L, Li Z, Han X, Wei X, Liu X. Lipid-AuNPs@ PDA nanohybrid for MRI/CT imaging and photothermal therapy of hepatocellular carcinoma. ACS Appl Mater Interfaces. 2014;6(16):14266–77.PubMedCrossRefGoogle Scholar
  160. 160.
    Ji DK, Zhang Y, Zang Y, Liu W, Zhang X, Li J, Chen GR, James TD, He XP. Receptor-targeting fluorescence imaging and theranostics using a graphene oxide based supramolecular glycocomposite. J Mater Chem B. 2015;3(47):9182–5.CrossRefGoogle Scholar
  161. 161.
    Quan S, Wang Y, Zhou A, Kumar P, Narain R. Galactose-based thermosensitive nanogels for targeted drug delivery of iodoazomycin arabinofuranoside (IAZA) for theranostic management of hypoxic hepatocellular carcinoma. Biomacromolecules. 2015;16(7):1978–86.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Lee MH, Sessler JL, Kim JS. Disulfide-based multifunctional conjugates for targeted theranostic drug delivery. Acc Chem Res. 2015;48(11):2935–46.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002;20(6):1668–76.CrossRefGoogle Scholar
  164. 164.
    Roy M, Finley J, Coskran T, Shen A, Xia S, Thuma B, Mascitti V. Characterization of asialoglycoprotein receptor (ASGPR) directed hepatocellular delivery using a pfizer developed targeting ligand PF-06853291. FASEB J. 2017;31(1_supplement):938–7.Google Scholar
  165. 165.
    Rajeev KG, Nair JK, Jayaraman M, Charisse K, Taneja N, O’Shea J, Willoughby JL, Yucius K, Nguyen T, Shulga-Morskaya S, Milstein S. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem. 2015;16(6):903–8.PubMedCrossRefGoogle Scholar
  166. 166.
    Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, Schmidt K, Zhao C, Aghajan M, Murray HF, Riney S. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014;42(13):8796–807.PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    A study of ALN-HBV in healthy adult volunteers and non-cirrhotic patients with chronic hepatitis B virus (HBV) infection [Internet]. NIH. 2016 [cited June 16, 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02826018?term=ALN-HBV&rank=1.
  168. 168.
    Terada T, Iwai M, Kawakami S, Yamashita F, Hashida M. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Release. 2006;111(3):333–42.PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Saugandha Das
    • 1
  • Pawan Kudale
    • 1
  • Prajakta Dandekar
    • 2
  • Padma V. Devarajan
    • 2
    Email author
  1. 1.Department of Pharmaceutical Sciences & TechnologyInstitute of Chemical TechnologyMumbaiIndia
  2. 2.Department of Pharmaceutical SciencesInsitute of Chemical Technology, Deemed University, Elite Status and Centre of Excellence, Government of MaharashtraMumbaiIndia

Personalised recommendations